Recent studies have demonstrated that tumor
angiogenesis is a prognostic factor for various malignant
neoplasms. Specifically, in non-small-cell lung
carcinomas (NSCLCs) most reports show an association
between neovascularization and vascular endothelial
growth factor (VEGF) expression as well as the presence
of metastases and survival, although a few reports do not
agree with these findings. Angiogenesis is not clearly
characterized in small-cell lung carcinomas (SCLCs),
since they are rarely treated by surgery, and thus the
available tissue for biological characterization is sparse.
The aim of the present study was to investigate
angiogenesis and the expression of VEGF in lung
tumors. We examined 88 non-small-cell and 39 smallcell
lung carcinomas. Angiogenesis was estimated by
determining microvessel counts, with the use of anti-
CD31 and anti-factor VIII antibodies and expression of
VEGF was also evaluated immunohistochemically. Our
data showed that in NSCLCs angiogenesis was more
prominent in poorly-differentiated neoplasms and
correlated with VEGF expression, therefore it is at least
in part mediated by the latter. Interestingly, in SCLCs a
higher vascularization was noted. However, there was no strong association with VEGF expression. Thus, smallcell
lung carcinoma may represent a suitable neoplasm
for testing antiangiogenic drugs in combination with
chemotherapy. Nevertheless, antiangiogenic therapy
should not be targeted specifically to the VEGF pathway,
since in SCLCs other mediators of angiogenesis may be
important as well